Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Risk adjustment effect on stroke clinical trials.

Karen C Johnston1, Alfred F Connors, Douglas P Wagner

  • 1Department of Neurology, University of Virginia, Charlottesville, USA. kj4v@virginia.edu

Stroke
|January 13, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Substance Use and Toxicology Screening in Young Adults With Acute Ischemic Stroke.

The Neurohospitalist·2026
Same author

Relation between Time from Onset to Randomization and Benefit Magnitude in Recent Clinical Trials of Thrombectomy for Patients with Large Ischemic Cores.

Annals of Indian Academy of Neurology·2026
Same author

2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association.

Stroke·2026
Same author

Blood Pressure and Low-Density Lipoprotein Cholesterol in Stroke Survivors Versus Controls in the United States From 1999 to 2018.

Stroke (Hoboken, N.J.)·2026
Same author

Food and Drug Administration Approval of Tenecteplase: What This Means for the Field of Acute Stroke Treatment.

Stroke (Hoboken, N.J.)·2026
Same author

Protect the integrity of the US National Institutes of Health.

Nature·2025
Same journal

Management of Patients at Risk of Ischemic Stroke With Left Ventricular Systolic Dysfunction in the Absence of Intracardiac Thrombus: A Scientific Statement From the American Heart Association.

Stroke·2026
Same journal

Update on Rehabilitation After Stroke: Global Changes and the Continued Importance of Therapy Intensity, Dose, and Timing.

Stroke·2026
Same journal

ENTF Neuromodulation Yields Reduced Disability After Stroke: An Individual Participant-Level Data Meta-Analysis.

Stroke·2026
Same journal

Menopause and Its Implications for Stroke in Women.

Stroke·2026
Same journal

Physician Approaches to Determining Goals of Stroke Care for Patients Living With Disability or Dementia: Results from the SEED Mixed-Methods Study.

Stroke·2026
Same journal

Aspirin for Stroke Primary Prevention: A Step Toward Genetic-Driven Personalized Medicine.

Stroke·2026
See all related articles

Risk adjustment in stroke trials reveals a larger treatment effect for tissue plasminogen activator (tPA). This method also reduces the necessary sample size for clinical studies.

Area of Science:

  • Neurology
  • Clinical Trials
  • Biostatistics

Background:

  • Ischemic stroke patient populations are diverse, complicating treatment effect estimation.
  • Dichotomous endpoints in randomized trials can introduce bias due to patient heterogeneity.
  • Risk adjustment is a statistical method to address heterogeneity and reduce bias.

Purpose of the Study:

  • To estimate the treatment effect of tissue plasminogen activator (tPA) in the NINDS tPA stroke data set.
  • To compare treatment effect estimates with and without adjustment for baseline patient differences.
  • To evaluate the impact of risk adjustment on sample size calculations for stroke trials.

Main Methods:

  • Utilized a prespecified predictive model to calculate odds ratios (ORs) for favorable outcomes.

Related Experiment Videos

  • Performed unadjusted and risk-adjusted analyses using the Barthel Index, NIH Stroke Scale, and Glasgow Outcome Scale.
  • Recalculated required sample size based on risk-adjusted analysis.

    • Main Results:

    • Analyzed data from 615 subjects.
    • Risk-adjusted ORs for the Barthel Index were higher (2.04) compared to unadjusted (1.76).
    • Similar increases in ORs were observed for NIH Stroke Scale and Glasgow Outcome Scale post-adjustment.
    • The estimated sample size for adjusted comparison was 13% smaller than for unadjusted.

    Conclusions:

    • Risk adjustment in the NINDS tPA data suggests a greater true treatment effect than previously estimated.
    • Prospective risk adjustment methodologies should be integrated into stroke clinical trials.
    • Risk adjustment enhances the precision of treatment effect estimates and optimizes trial efficiency.